Dr David D. Chang
David Chang, MD, PhD, has an industry-leading track record of innovation within oncology drug development. Most recently, he held senior leadership roles during his more than decade-long tenure at Amgen, including as Vice President of Global Development and Head of Hematology-Oncology. Dr. Chang spearheaded personalized therapy strategies underlying the success of a colon cancer drug at Amgen and ran the pivotal programs for a bispecific T cell engager antibody in acute lymphocytic leukemia and for a first-of-its-kind oncolytic immunotherapy in melanoma. Dr. Chang's areas of responsibility at Amgen included: global regulatory interactions; product commercialization strategies; evaluation of business development opportunities, and integration of key acquisitions. Prior to joining Amgen in 2002, Dr. Chang held dual appointments as associate professor of medicine and of microbiology, immunology and molecular genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He obtained his B.S. degree in Biology from the Massachusetts Institute of Technology and his M.D. and Ph.D. degrees from Stanford University. Dr. Chang also completed his internship and residency in internal medicine at Brigham and Women's Hospital and his fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow.